A marriage of formal methods and LLMs seeks to harness the strengths of both.
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Intelligencer on MSN
The Singularity Is Going Viral
AI insiders and outsiders are both feeling helpless about the same thing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results